Venlafaxine-tranylcypromine

From Psychiatrienet
Revision as of 16:13, 20 November 2009 by Mariska (talk | contribs)
Jump to: navigation, search
Venlafaxine
Type Antidepressant
Group SNRI
links
Medscape Venlafaxine
PubChem 5656
PubMed Venlafaxine
Kompas (Dutch) Venlafaxine
Wikipedia Venlafaxine
Tranylcypromine
Type Antidepressant
Group MAO-I
links
Medscape Tranylcypromine
PubChem 5530
PubMed Tranylcypromine
Kompas (Dutch) Tranylcypromine
Wikipedia Tranylcypromine

Switch medication from venlafaxine to tranylcypromine.[1] [2]

Nietinrijdenbord.png Stop venlafaxine
  • Before day 1: gradually reduce dosage of venlafaxine to a maximum of 75 mg/ day.
  • Day 1: reduce a dosage of 75 mg/day to 37,5 mg/day.
  • Day 8: stop administration of venlafaxine.
Eenrichtingbord.png Start tranylcypromine
  • Day 8-14: a wash-out period one week is necessary.
  • Day 15: start administration of tranylcypromine in a low dosage of 20 mg/day for one week.
  • Day 22: after this week the dosage of tranylcypromine can be increased if necessary.
Letopbord.png Cave
  • Occurrence of serotonin syndrome is reported when a wash-out period (of one week) is not considered.


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.